Send this to a friend

Biostage eyes FDA application in 2019

Despite just $5.8 million in cash to its name, Holliston organ bioengineering firm Biostage is eyeing a 2019 U.S. Food and Drug Administration application for its esophagus-regenerating device.
With no product on the market, the company reported no revenue in the second quarter, but was able to significantly reduce its expense. As a result, the company’s net loss of $2.1 million was a decrease of 71 percent compared to the same period last ye ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media